Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of subcutaneous guselkumab induction therapy in moderately to severely active ulcerative colitis
CTR20223406Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of guselkumab in autoimmune colitis, sponsored by Janssen Pharmaceutical. Started Apr 2023; status: active.
02
Drugs
guselkumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20223406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223406.